Literature DB >> 10416612

Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo.

D C Duffey1, Z Chen, G Dong, F G Ondrey, J S Wolf, K Brown, U Siebenlist, C Van Waes.   

Abstract

We demonstrated recently that constitutive expression of proinflammatory cytokines interleukin (IL)-1alpha, IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor in head and neck squamous cell carcinoma is correlated with activation of transcription factor nuclear factor (NF)-kappaB/Rel A (p50/p65), which binds the promoter region within each of the genes encoding this repertoire of cytokines. NF-kappaB can be activated after signal-dependent phosphorylation and degradation of inhibitor-kappaBalpha and has been reported to promote cell survival and growth. In the present study, we expressed a phosphorylation site mutant of inhibitor-kappaBalpha (IkappaBalphaM) in head and neck squamous cell carcinoma lines UM-SCC-9, -11B, and -38 to determine the effect of inhibition of NF-kappaB on cytokine expression, cell survival in vitro, and growth in vivo. After transfection with IKBalphaM, only a few UM-SCC-9 clones were obtained that stably expressed the mutant IkappaB, suggesting that expression of a mutant IkappaBalpha may affect survival of the transfected UM-SCC cell lines. After cotransfection of IkappaBalphaM with a Lac-Z reporter, we found that the number of surviving beta-galactosidase-positive cells in the three cell lines was reduced by 70-90% when compared with controls transfected with vector lacking the insert. In UM-SCC-9 cells that stably expressed IkappaBalphaM, inhibition of constitutive and tumor necrosis factor-a induced NF-kappaB activation, and production of all four cytokines was observed. Although UM-SCC-9 IkappaBalphaM-transfected cells proliferated at the same rate as vector-transfected cells in vitro, a significant reduction in growth of tumor xenografts was observed in SCID mice in vivo. The decreased growth of UM-SCC-9 IkappaBalphaM-transfected tumor cells accompanied decreased immunohistochemical detection of the activated form of NF-kappaB in situ. These results provide evidence that NF-KB and IkappaBalpha play an important role in survival, constitutive and inducible expression of proinflammatory cytokines, and growth of squamous cell carcinoma. NF-kappaB could serve as a potential target for therapeutic intervention against cytokine and other immediate-early gene responses that contribute to the survival, growth, and pathogenesis of these cancers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416612

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  76 in total

1.  Phosphatidylcholine-specific phospholipase C and phospholipase D are respectively implicated in mitogen-activated protein kinase and nuclear factor kappaB activation in tumour-necrosis-factor-alpha-treated immature acute-myeloid-leukaemia cells.

Authors:  I Plo; D Lautier; T Levade; H Sekouri; J P Jaffrézou; G Laurent; A Bettaïeb
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

Review 2.  NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions.

Authors:  Jorge Caamaño; Christopher A Hunter
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

3.  Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkappaBalpha degradation in B cells.

Authors:  Shelby O'Connor; Stuart D Shumway; Ian J Amanna; Colleen E Hayes; Shigeki Miyamoto
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

4.  Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.

Authors:  Henrike Westekemper; Michael Freistuehler; Norbert Bornfeld; Klaus-Peter Steuhl; Max Scheulen; Ralf A Hilger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-11       Impact factor: 3.117

Review 5.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

Review 6.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

7.  Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B.

Authors:  Sébastien Jeay; Stefania Pianetti; Herbert M Kagan; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

8.  miR-506 contributes to malignancy of cutaneous squamous cell carcinoma via targeting of P65 and LAMC1.

Authors:  Jian Zhou; Ying Zhang; Zhaofeng Han; Zhiwei Dong; Tongtong Cao; Aizhou Wei; Pengfei Guo; Qingnan Meng
Journal:  Cell Cycle       Date:  2019-01-24       Impact factor: 4.534

9.  Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype.

Authors:  Baisakhi Raychaudhuri; Yulong Han; Tao Lu; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2007-05-04       Impact factor: 4.130

10.  Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.

Authors:  Changyou Li; Rongxiu Li; Jennifer R Grandis; Daniel E Johnson
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.